New triple therapy aims to slow Organ-Spread breast cancer
NCT ID NCT07467330
First seen Mar 19, 2026 · Last updated May 13, 2026 · Updated 8 times
Summary
This study tests whether adding a low-dose chemotherapy pill (capecitabine) to the standard two-drug combination (dalpiciclib plus hormone therapy) can help control HR+/HER2- breast cancer that has spread to organs like the liver or lungs. About 258 women with advanced disease will be randomly assigned to receive either the three-drug combo or the standard two drugs. The goal is to see if the triple therapy delays cancer growth longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hosptial
RECRUITINGFuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.